NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomicsNeoGenomics(US:NEO) Businesswire·2026-08-27 04:17

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors. ...

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring - Reportify